Heparin Induced Thrombocytopenia

Suitable for clinicians and hematology consultants, this title includes: coverage of approved and novel pharmacotherapies, dosing guidelines, and the advantages and limitations of alternative anticoagulants; review of the immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies; and more. Although first reported in 1973, immune heparin-induced thrombocytopenia (HIT) remains one of the most frequent and devastating adverse drug reactions encountered by physicians. This thoroughly updated fifth edition from international experts Professors Warkentin and Greinacher is the gold standard for accurate diagnosis and management of this condition. Identifying key signs and symptoms and providing clear intervention strategies—including the use of alternative anticoagulants to manage critical circumstances—this is an essential resource for all clinicians and a "must" for hematology consultants. Heparin-Induced Thrombocytopenia, Fifth Edition explores: Clinical and laboratory studies on HIT The immune basis and pathogenesis, animal models, and laboratory testing for HIT antibodies Clinical features, differential diagnosis, scoring systems, and frequency of HIT in diverse clinical settings, including pediatric patients Evidence-based guidelines for recognition, treatment, and prevention Actions that should and should not be taken after the identification of HIT Traditional and novel pharmacotherapies, current dosing guidelines, and the advantages and limitations of alternative anticoagulants Selection criteria from a variety of new treatment options, helping physicians determine which of these agents are safe and effective for their patients

Taking the advances in clinical recognition, laboratory testing, and pharmacologic therapy as well as basic aspects of pathogenesis. This book reinforces its standing as the guide to accurate diagnosis and effective management of this condition. It features chapters on bivalirudin and pediatric heparin-induced thrombocytopenia (HIT). Taking stock of advances in clinical recognition, laboratory testing, and pharmacologic therapy as well as basic aspects of pathogenesis, the Third Edition of Heparin-Induced Thrombocytopenia reinforces its standing as the leading guide to accurate diagnosis and effective management of this complex condition. Featuring added chapters on bivalirudin and pediatric heparin-induced thrombocytopenia (HIT), this reference also updates all 20 chapters of the previous edition to regard anew such topics as management of HIT using direct thrombin inhibitors and the special problems of renal failure and cardiac surgery in HIT patients.